inflammatory bowel disease
Dashboard Shortens Therapy Gaps And Speeds Medication Delivery
Specialty pharmacists at Vanderbilt Health built user-friendly dashboards that have improved the speed of coverage ...
JUNE 15, 2025
IBD Patients Often Make Hard Choices to Access Therapy
Patients with IBD face an array of challenges in maintaining adherence to therapy, particularly with respect to ...
APRIL 26, 2025
Just Say No to Paying Cybersecurity Ransom
Health systems and other sites of care should never pay a ransom demand from a cyberattacker, even if that seems to ...
MARCH 20, 2025
Study Finds GLP-1s Safe and Effective For Managing Obesity in Patients With IBD
GLP-1s are well tolerated and effective for weight loss in patients with IBD, according to new research
NOVEMBER 6, 2024
Malnutrition Is Endemic to IBD, but Can Be Managed
Correcting the harms of malnutrition in inflammatory bowel disease often leads to better response to biologic ...
AUGUST 14, 2024
Subcutaneous Infliximab or Vedolizumab For Maintenance Therapy in IBD; Fast-Acting Upadacitinib in Crohn’s
In this month’s The Regueiro Report, I highlight two studies on medications to treat inflammatory bowel ...
JUNE 27, 2024
FDA Approves Risankizumab for Ulcerative Colitis
The FDA has approved risankizumab (Skyrizi, AbbVie) for patients with moderate to severe ulcerative colitis.
JUNE 27, 2024
Anti–IL-23 Agents Effective After Prior UC Treatment Failure
VANCOUVER, B.C.—Two different monoclonal antibodies targeting the interleukin-23 p19 subunit achieved all of ...
JANUARY 26, 2024
Advanced Therapy Combinations Show Promise in Treating IBD
Therapeutic strategies employing a combination of advanced therapies are starting to reveal promising outcomes in ...
JANUARY 17, 2024
Advanced Therapies for IBD Do Not Appear To Raise Thrombotic Risk
In patients with IBD, neither biologics nor small molecule targeted therapies increase the risk for major adverse ...
DECEMBER 30, 2023
FDA Approves Omvoh for Adults With Moderately to Severely Active Ulcerative Colitis
The FDA approved mirikizumab-mrkz (Omvoh, Eli Lilly) infusion for the treatment of moderately to severely active ...
OCTOBER 27, 2023
FDA Approves Zymfentra for IBD
The FDA approved Zymfentra for the treatment of inflammatory bowel disease.
OCTOBER 27, 2023
